File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.exphem.2008.06.008
- Scopus: eid_2-s2.0-53749106408
- PMID: 18715686
- WOS: WOS:000260617300015
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: MHC expression kinetics and immunogenicity of mesenchymal stromal cells after short-term IFN-gamma challenge.
Title | MHC expression kinetics and immunogenicity of mesenchymal stromal cells after short-term IFN-gamma challenge. |
---|---|
Authors | |
Issue Date | 2008 |
Publisher | Elsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/exphem |
Citation | Experimental Hematology, 2008, v. 36 n. 11, p. 1551-1561 How to Cite? |
Abstract | OBJECTIVE: Under the influence of interferon-gamma (IFN-gamma), mesenchymal stromal cells (MSCs) are conditional antigen-presenting cells, which have immunosuppressive potential. Apart from IFN-gamma upregulation of major histocompatibility complexes class I and II (MHC-I and MHC-II) expression, the underlying kinetics and mechanisms have not been described previously. This information is helpful to delineate how human MSCs can be modulated by IFN-gamma in different clinical scenarios. MATERIALS AND METHODS: Here, we demonstrated that IFN-gamma-treated MSCs underwent classical signal transduction pathway via phosphorylation of signal transducers and activators of transcription-1, activation of interferon regulatory factor-1, and class II transactivator comparable to that of primary human blood macrophages. RESULTS: IFN-gamma markedly induced expression of MHC-I instantly, while its effects on MHC-II were less dramatic and delayed up to 4 days. This is due to a slower intracellular transport of the MHC-II antigen to the membrane surface. More important is that MSCs showed a reduction in their proliferation by 50% without evidence of cell death after prolonged IFN-gamma treatment for 8 days. High-dose IFN-gamma-treated MSCs (500 U/mL) could initiate T-cell activation as indicated by expression of CD25 and proliferation of allogeneic T cells. CONCLUSIONS: The summative IFN-gamma effects will adversely affect the immunoprivilege status and lifespan of MSCs. |
Persistent Identifier | http://hdl.handle.net/10722/170408 |
ISSN | 2022 Impact Factor: 2.6 2020 SCImago Journal Rankings: 1.386 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chan, WK | en_US |
dc.contributor.author | SikYin Lau, A | en_US |
dc.contributor.author | ChunBong Li, J | en_US |
dc.contributor.author | KaWai Law, H | en_US |
dc.contributor.author | Lau, YL | en_US |
dc.contributor.author | ChiFung Chan, G | en_US |
dc.date.accessioned | 2012-10-30T06:08:13Z | - |
dc.date.available | 2012-10-30T06:08:13Z | - |
dc.date.issued | 2008 | en_US |
dc.identifier.citation | Experimental Hematology, 2008, v. 36 n. 11, p. 1551-1561 | en_US |
dc.identifier.issn | 0301-472X | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/170408 | - |
dc.description.abstract | OBJECTIVE: Under the influence of interferon-gamma (IFN-gamma), mesenchymal stromal cells (MSCs) are conditional antigen-presenting cells, which have immunosuppressive potential. Apart from IFN-gamma upregulation of major histocompatibility complexes class I and II (MHC-I and MHC-II) expression, the underlying kinetics and mechanisms have not been described previously. This information is helpful to delineate how human MSCs can be modulated by IFN-gamma in different clinical scenarios. MATERIALS AND METHODS: Here, we demonstrated that IFN-gamma-treated MSCs underwent classical signal transduction pathway via phosphorylation of signal transducers and activators of transcription-1, activation of interferon regulatory factor-1, and class II transactivator comparable to that of primary human blood macrophages. RESULTS: IFN-gamma markedly induced expression of MHC-I instantly, while its effects on MHC-II were less dramatic and delayed up to 4 days. This is due to a slower intracellular transport of the MHC-II antigen to the membrane surface. More important is that MSCs showed a reduction in their proliferation by 50% without evidence of cell death after prolonged IFN-gamma treatment for 8 days. High-dose IFN-gamma-treated MSCs (500 U/mL) could initiate T-cell activation as indicated by expression of CD25 and proliferation of allogeneic T cells. CONCLUSIONS: The summative IFN-gamma effects will adversely affect the immunoprivilege status and lifespan of MSCs. | en_US |
dc.language | eng | en_US |
dc.publisher | Elsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/exphem | en_US |
dc.relation.ispartof | Experimental hematology | en_US |
dc.rights | Experimental Hematology. Copyright © Elsevier Inc. | - |
dc.subject.mesh | Cell Proliferation - Drug Effects | en_US |
dc.subject.mesh | Histocompatibility Antigens Class I - Analysis | en_US |
dc.subject.mesh | Histocompatibility Antigens Class Ii - Analysis | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Interferon-Gamma - Pharmacology | en_US |
dc.subject.mesh | Lymphocyte Activation | en_US |
dc.subject.mesh | Mesenchymal Stem Cells - Drug Effects - Immunology | en_US |
dc.subject.mesh | T-Lymphocytes, Regulatory - Drug Effects - Immunology | en_US |
dc.title | MHC expression kinetics and immunogenicity of mesenchymal stromal cells after short-term IFN-gamma challenge. | en_US |
dc.type | Article | en_US |
dc.identifier.email | SikYin Lau, A:asylau@hku.hk | en_US |
dc.identifier.email | Lau, YL:lauylung@hkucc.hku.hk | en_US |
dc.identifier.email | ChiFung Chan, G:gcfchan@hkucc.hku.hk | en_US |
dc.identifier.authority | SikYin Lau, A=rp00474 | en_US |
dc.identifier.authority | Lau, YL=rp00361 | en_US |
dc.identifier.authority | ChiFung Chan, G=rp00431 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1016/j.exphem.2008.06.008 | - |
dc.identifier.pmid | 18715686 | - |
dc.identifier.scopus | eid_2-s2.0-53749106408 | en_US |
dc.identifier.hkuros | 153945 | - |
dc.identifier.volume | 36 | en_US |
dc.identifier.issue | 11 | en_US |
dc.identifier.spage | 1561 | en_US |
dc.identifier.epage | 1551 | en_US |
dc.identifier.isi | WOS:000260617300015 | - |
dc.publisher.place | United States | en_US |
dc.identifier.scopusauthorid | Chan, WK=35080149500 | en_US |
dc.identifier.scopusauthorid | SikYin Lau, A=7202626202 | en_US |
dc.identifier.scopusauthorid | ChunBong Li, J=24544452200 | en_US |
dc.identifier.scopusauthorid | KaWai Law, H=24544482700 | en_US |
dc.identifier.scopusauthorid | Lau, YL=7201403380 | en_US |
dc.identifier.scopusauthorid | ChiFung Chan, G=16160154400 | en_US |
dc.identifier.issnl | 0301-472X | - |